New neurodevelopmental syndrome identified
News Apr 21, 2016
Study pinpoints underlying genetic mutations, raising hopes for targeted therapies -
A multicenter research team led by Columbia University Medical Center (CUMC) has discovered a new neurodevelopmental syndrome and the genetic mutations that cause it. The discovery is an important step toward creating targeted therapies for individuals with this syndrome, which causes severe developmental delays, abnormal muscle tone, seizures, and eye complications.
The study is published online today in the American Journal of Human Genetics.
"Now that we've determined that a small subset of patients with neurodevelopmental disabilities share the same mutations, we can begin to learn about the prognosis of these individuals, how these mutations lead to this syndrome, and how to develop targeted therapies," said study leader David Goldstein, PhD.
The discovery was made by performing whole-exome sequencing of patients with an undiagnosed neurodevelopmental disorder to identify excess spontaneous, or non-inherited, mutations. (The exome is the portion of the genome that encodes for the production of proteins).
"Of the hundreds of patients we sequenced at CUMC, three were found to have mutations in a gene called GNB1," said Slave Petrovski, PhD, first author of the report. "We then reached out to our colleagues at other medical centers to see if they found similar mutations in any of the patients whose DNA they had sequenced. In all, we reviewed sequencing data on 5,855 individuals and found a total of 13 individuals with GNB1 mutations."
GNB1 mutations have been detected in some cancers, but this is the first time the mutations have been linked to a neurodevelopmental disorder. GNB1 encodes a protein that functions in the transmission of many different kinds of signals within cells.
"As of yet, we don't know which aspect of that signaling is affected by these mutations," said Goldstein. "Moving forward, we hope to determine exactly how these mutations cause disease and then use that information to identify druggable targets—completing the entire precision medicine circle for this condition, from gene discovery to functional biology to the development of targeted therapeutics."
Whole-exome sequencing is currently not a standard part of the evaluation of patients with neurodevelopmental disorders. "With more discoveries like this one, this genetic approach to disease diagnosis will become standard practice for all patients with these disabilities," said Goldstein.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Petrovski S et al. Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. American Journal of Human Genetics, Published Online April 21 2016. doi: 10.1016/j.ajhg.2016.03.011
All in a Droplet: Atomic Resolution of ALS Protein ResolvedNews
Researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases of muscle and bone.READ MORE
Pupil Size Couples to Cortical States to Protect Deep Sleep StabilityNews
Researchers have found that mice pupil size fluctuates during sleep. They also show that pupil size is a reliable indicator of sleep states.READ MORE
A Place to Think: Persistent neuronal activity in human prefrontal cortex links perception and actionNews
Neuroscientists have tracked the progress of a thought through the brain, showing clearly how the prefrontal cortex at the front of the brain coordinates activity to help us act in response to a perception.READ MORE